Anika Therapeutics (ANIK) Misses Q1 EPS by 2c

Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $26.17 million versus the consensus estimate of $28.13 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

You May Also Be Interested In

• Wolverine World Wide (WWW) Tops Q2 EPS by 2c; offers guidance
• Idaho Strategic Resources, Inc. (IDR) Misses Q2 EPS by 4c
• Cheniere Energy (LNG) PT Raised to $300 at Mizuho